Torna alla classifica

Sotera Health Company (SHC)

NEUTRAL
HealthcareDiagnostics & ResearchUnited States

Fondamentale

58

Prezzo

$19.54

Capitalizzazione

$5.48B

Parte 1 · Quanto vale l'azienda

Panoramica

Sotera Health Company provides sterilization solutions, lab testing, and advisory services for the healthcare industry in the United States, Canada, Europe, and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. The Sterigenics segment offers outsourced terminal sterilization and irradiation services using gamma irradiation, ethylene oxide processing, and electron beam irradiation technologies for medical devices, pharmaceutical, and food safety and advanced applications markets. The Nordion segment provides Cobalt-60 used in the sterilization and irradiation processes for the medical device, pharmaceutical, food safety, and high-performance materials industries, as well as in the treatment of cancer. It also offers gamma irradiation systems. The Nelson Labs segment provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2015 and is headquartered in Broadview Heights, Ohio.

Per questa società non c'è ancora una scheda redazionale

Concorrenti diretti

Con chi questa società si contende gli stessi clienti

Per questa società non c'è ancora una scheda redazionale

Per questa società non c'è ancora un elenco di concorrenti.

Stato Patrimoniale e Liquidità

Ricavi

$1.22B

Ultimi 12 mesi (al 30/06/2026)

Utile Netto

$163M

Ultimi 12 mesi (al 30/06/2026)

Free Cash Flow

$149M

Patrimonio Netto Totale

$606M

Passività Totali

$2.66B

Rapporto di Liquidità

2.80

Copertura Interessi

-

Debito/EBITDA

3.93

Utile per Azione

Ricavi e Utile Netto

Free Cash Flow

Scomposizione Ricavi

Prospetto storico

Margini nel tempo

Il debito nel tempo

Quanto pesa il debito

Griglia della crescita

Crescita — Ricavi

Stima del Fair Value

Caso generaleSopravvalutato

Fair Value

$13.10

Prezzo Attuale

$19.54

Margine di Sicurezza

-49.1%

Range Fair Value

$8.52 - $17.69

Metodi di Stima

Target degli analisti:$22.72
Flussi di cassa scontati (DCF):$6.90
Multiplo sugli utili (P/E):$9.99
Formula di Graham:$9.28
Valore della capacità di reddito (EPV):$6.43
P/B giustificato:$3.14
Sconto dei dividendi (Gordon):Dati insufficienti per calcolarlo
P/FFO, i fondi da operazioni:Dati insufficienti per calcolarlo
Utili di mezzo ciclo:$23.68
Multiplo sui ricavi:Dati insufficienti per calcolarlo
Consenso Analisti:Strong Buy (12B / 3H / 0S)
Ultima Sorpresa Utili:+7.62%

Metriche di Valutazione

Rapporto P/E

33.63

ROE

12.9%

Rapporto P/B

8.22

P/FCF

48.54

Margine Lordo

55.0%

ROIC

-

Radar Redditività

Creazione di Valore (Vantaggio Competitivo)

ROIC

-

WACC

10.4%

ROIC − WACC

-

Criteri di Analisi Fondamentale

Superati (13)

  • EPS shows upward trend
  • Gross Margin 55.0%
  • Positive Free Cash Flow
  • Current Ratio
  • Debt/EBITDA
  • Return on Tangible Assets
  • ROE 20.6%
  • Revenue Growth 5Y 7.3%
  • Analyst Consensus 80% Buy
  • Earnings Surprise avg 8.4%
  • Earnings Quality (OCF/NI) 1.79
  • Net Margin Trend 13.4% vs 2.1%
  • Piotroski F-Score 6/9

Non superati (9)

  • Price CAGR -5.48%
  • P/FCF 48.54
  • P/B Ratio 8.22
  • Debt/Equity ratio
  • CapEx intensity
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • Share Dilution 4.0%

Non disponibili (5)

  • ROIC NaN%
  • Dividend Payout NaN%
  • Operating Margin NaN%
  • Interest Coverage
  • PEG Ratio (need PE > 0 and growth > 0)

Piotroski F-Score

6/9

Segnali misti: alcune aree necessitano attenzione

score
criteria

Qualità degli Utili

1.79

Alta qualità: utili supportati da cash

Diluizione Azionaria

4.0%

Emissione nuove azioni, diluizione proprietà

Governance

Team Dirigenziale

NomeRuoloEtà
Mr. Michael B. Petras Jr.Executive Chairman of the Board56
Mr. Jonathan M. LyonsSenior VP & CFO47
Mr. Michael P. RutzPresident of Sterigenics U.S., LLC54
Mr. Alton E. ShaderCEO & Director52
Mr. Robert G. HauzieChief Information Officer-
Ms. Erika OstrowskiSenior VP, General Counsel & Corporate Secretary-
Ms. Kristin A. GibbsChief Marketing Officer-
Mr. William O. Lehmann Jr., J.D., M.B.A.Senior Vice President of Strategy & Corporate Development59
Ms. Sally R. TurnerChief Human Resources Officer-
Ms. Danielle J. MentureSenior Vice President of Global Environmental, Health & Safety and Sustainability-

Rischio Audit

4

Rischio CdA

7

Rischio Compensi

5

Rischio Diritti Azionisti

7

Parte 2 · Il prezzo e il momento d'ingresso

Questa parte non serve a capire se l'azienda vale: serve a scegliere quando comprarla, dopo che i fondamentali ti hanno convinto. Dentro: analisi tecnica, potenziale, drawdown storici, esposizione gamma.

Ultime Notizie

Ultime notizie per SHC, da Markets Gazette.

  • 3/15/2026NEUTRAL
    Sotera Health Shares Rise 18% in a Year. Here's What a $37 Million Stake Trim Signals

    Sotera Health Company shares have seen an 18% increase over the past year, with recent activity indicating a significant stake trim by an insider amounting to $37 million. Sotera Health provides crucial sterilization and laboratory testing services to highly regulated industries globally, playing a vital role in maintaining essential supply chains. While the stock has performed well, the substantial insider sale could signal a divergence of opinion on future valuation or a need for liquidity, warranting investor attention.

  • 3/2/2026NEGATIVE
    Sotera Health Up 30% This Past Year, so Why Did One Fund Sell $4 Million in Shares?

    Sotera Health, a global provider of sterilization and laboratory solutions to the healthcare, pharmaceutical, and food industries, has seen an impressive 30% growth over the past year. Despite this robust performance, an unidentified fund divested $4 million worth of shares. This move raises questions among investors: why would an institutional entity sell such a significant stake in a rapidly growing company? It could signal strategic profit-taking, a portfolio rebalancing, or potentially a less optimistic view on the company's future prospects not yet apparent to the broader market. Investors should closely monitor upcoming developments and the rationale behind this significant divestment.

  • 2/24/2026NEUTRAL
    Insights into Sotera Health Q4 Earnings

    Investors are keenly awaiting insights into Sotera Health's fourth-quarter earnings, a pivotal event for assessing the company's performance and future outlook. Analyzing quarterly results is crucial for understanding financial health, revenue growth, and profitability, all of which directly influence market sentiment and investment decisions. While specific details are yet to be disclosed, market focus remains on how Sotera Health navigated operational challenges and opportunities during the period. Key data points, such as revenue, earnings per share (EPS), and future guidance, will be scrutinized to identify trends and potential catalysts for the stock price. Results meeting or exceeding expectations could bolster confidence, whereas a disappointment might trigger a negative reaction.

via Markets Gazette